Neuphoria Therapeutics Inc. Deferred Income Tax Liabilities, Net
Neuphoria Therapeutics Inc. (NEUP) had Deferred Income Tax Liabilities, Net of $355.94 thousand as of 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-09-18
- 2026-06-30: Deferred Income Tax Liabilities, Net $355.94K.
- 2026-03-31: Deferred Income Tax Liabilities, Net $390.73K.
- 2025-12-31: Deferred Income Tax Liabilities, Net $425.53K.
- 2025-09-30: Deferred Income Tax Liabilities, Net $460.32K.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2026-06-30 | $355.94K 10-K · filed 2026-09-18 |
| 2026-03-31 | $390.73K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $425.53K 10-Q · filed 2026-02-17 |
| 2025-09-30 | $460.32K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $495.11K 10-K · filed 2026-09-18 |
| 2025-03-31 | $761.74K 10-Q · filed 2025-05-20 |
| 2024-12-31 | $842.92K 10-Q · filed 2025-02-14 |
| 2024-09-30 | $831.32K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $963.54K 10-K · filed 2025-09-29 |
| 2023-06-30 | $1.10M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |